THC Therapeutics, Inc. Logo

THC Therapeutics, Inc.

THCT

(1.8)
Stock Price

0,00 USD

-16321.45% ROA

16.08% ROE

-0.17x PER

Market Cap.

120.678,00 USD

-20.32% DER

0% Yield

0% NPM

THC Therapeutics, Inc. Stock Analysis

THC Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

THC Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (70.17%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (-0x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-14%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROA

The stock's ROA (-6711.69%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

THC Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

THC Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

THC Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

THC Therapeutics, Inc. Revenue
Year Revenue Growth
2007 200
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

THC Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 9.000 100%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

THC Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 0
2008 8.410 100%
2009 0 0%
2010 115.411 100%
2011 23.572 -389.61%
2012 240.352 90.19%
2013 364.699 34.1%
2014 552.830 34.03%
2015 273.276 -102.3%
2016 92.848 -194.33%
2017 276.158 66.38%
2018 744.484 62.91%
2019 24.234.371 96.93%
2020 1.298.296 -1766.63%
2021 939.977 -38.12%
2022 1.746.028 46.16%
2023 430.248 -305.82%
2023 306.163 -40.53%
2024 340.604 10.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

THC Therapeutics, Inc. EBITDA
Year EBITDA Growth
2007 -153
2008 -8.410 98.18%
2009 -68.790 87.77%
2010 -124.411 44.71%
2011 -23.572 -427.79%
2012 -240.352 90.19%
2013 -1.127.616 78.68%
2014 -554.913 -103.21%
2015 -273.276 -103.06%
2016 -92.848 -194.33%
2017 -276.158 66.38%
2018 -744.484 62.91%
2019 -24.234.371 96.93%
2020 -1.298.296 -1766.63%
2021 -923.607 -40.57%
2022 -1.733.694 46.73%
2023 -428.844 -304.27%
2023 -492.519 12.93%
2024 -339.200 -45.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

THC Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
2007 200
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 -10.491 100%
2018 -25.434 58.75%
2019 -25.558 0.49%
2020 -20.114 -27.07%
2021 -16.370 -22.87%
2022 -12.334 -32.72%
2023 0 0%
2023 -1.393 100%
2024 -1.404 0.78%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

THC Therapeutics, Inc. Net Profit
Year Net Profit Growth
2007 -153
2008 -8.490 98.2%
2009 -68.873 87.67%
2010 -37.864 -81.9%
2011 -24.772 -52.85%
2012 -241.552 89.74%
2013 -1.133.126 78.68%
2014 -576.046 -96.71%
2015 -284.299 -102.62%
2016 -91.998 -209.03%
2017 -15.598.422 99.41%
2018 -6.139.400 -154.07%
2019 -23.610.650 74%
2020 -2.412.879 -878.53%
2021 -2.437.195 1%
2022 -1.291.830 -88.66%
2023 -16.644.168 92.24%
2023 -387.036 -4200.42%
2024 -2.287.900 83.08%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

THC Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 -2 100%
2014 -1 -100%
2015 -1 0%
2016 0 0%
2017 -2 100%
2018 -1 0%
2019 -2 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 -1 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

THC Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
2007 147
2008 -7.997 101.84%
2009 -7.437 -7.53%
2010 -75.655 90.17%
2011 -10.983 -588.84%
2012 -433.500 97.47%
2013 -111.246 -289.68%
2014 -91.782 -21.21%
2015 -11.919 -670.05%
2016 -17.318 31.18%
2017 -176.733 90.2%
2018 -190.697 7.32%
2019 -330.998 42.39%
2020 -587.933 43.7%
2021 -388.477 -51.34%
2022 -418.917 7.27%
2023 -85.432 -390.35%
2023 -21.485 -297.64%
2024 -45.128 52.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

THC Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 147
2008 -7.997 101.84%
2009 -7.437 -7.53%
2010 -75.655 90.17%
2011 -10.983 -588.84%
2012 -258.500 95.75%
2013 -111.246 -132.37%
2014 -91.782 -21.21%
2015 -11.919 -670.05%
2016 -17.318 31.18%
2017 -156.733 88.95%
2018 -190.165 17.58%
2019 -329.803 42.34%
2020 -587.933 43.9%
2021 -388.477 -51.34%
2022 -418.917 7.27%
2023 -85.432 -390.35%
2023 -21.485 -297.64%
2024 -45.128 52.39%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

THC Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 175.000 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 20.000 100%
2018 532 -3659.4%
2019 1.195 55.48%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

THC Therapeutics, Inc. Equity
Year Equity Growth
2007 16.072
2008 7.582 -111.98%
2009 -68.510 111.07%
2010 -40.164 -70.58%
2011 -64.936 38.15%
2012 206.012 131.52%
2013 47.053 -337.83%
2014 -188.517 124.96%
2015 -277.459 32.06%
2016 -144.457 -92.07%
2017 4.848.411 102.98%
2018 1.938.090 -150.16%
2019 -749.406 358.62%
2020 -1.778.651 57.87%
2021 -2.477.326 28.2%
2022 -3.109.967 20.34%
2023 -5.222.989 40.46%
2023 -3.309.833 -57.8%
2024 -3.895.373 15.03%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

THC Therapeutics, Inc. Assets
Year Assets Growth
2007 17.072
2008 9.075 -88.12%
2009 1.638 -454.03%
2010 10.983 85.09%
2011 0 0%
2012 595.393 100%
2013 192.767 -208.87%
2014 181.372 -6.28%
2015 181.953 0.32%
2016 175.780 -3.51%
2017 5.159.300 96.59%
2018 2.519.534 -104.77%
2019 520.022 -384.51%
2020 85.346 -509.31%
2021 480.068 82.22%
2022 206.901 -132.03%
2023 56.613 -265.47%
2023 12.990 -335.82%
2024 14.819 12.34%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

THC Therapeutics, Inc. Liabilities
Year Liabilities Growth
2007 1.000
2008 1.493 33.02%
2009 70.148 97.87%
2010 51.147 -37.15%
2011 64.936 21.23%
2012 389.381 83.32%
2013 145.714 -167.22%
2014 369.889 60.61%
2015 459.412 19.49%
2016 320.237 -43.46%
2017 310.889 -3.01%
2018 581.444 46.53%
2019 1.269.428 54.2%
2020 1.863.997 31.9%
2021 2.957.394 36.97%
2022 3.316.868 10.84%
2023 5.279.602 37.18%
2023 3.222.823 -63.82%
2024 3.810.192 15.42%

THC Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.02
Price to Earning Ratio
-0.17x
Price To Sales Ratio
0x
POCF Ratio
-2.07
PFCF Ratio
-2.53
Price to Book Ratio
-0.03
EV to Sales
0
EV Over EBITDA
-3.61
EV to Operating CashFlow
-19.08
EV to FreeCashFlow
-19.08
Earnings Yield
-5.81
FreeCashFlow Yield
-0.39
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.22
Graham NetNet
-0.12

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.08
ROE
0.17
Return On Assets
-47.64
Return On Capital Employed
0.17
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
0
Effective Tax Rate
0.08

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.08
Return on Tangible Assets
-163.21
Days Sales Outstanding
0
Days Payables Outstanding
541681.22
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,12
Tangible Book Value per Share
-0.12
Shareholders Equity per Share
-0.12
Interest Debt per Share
0.03
Debt to Equity
-0.2
Debt to Assets
53.41
Net Debt to EBITDA
-3.13
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-3795373
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.76
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
6.56

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

THC Therapeutics, Inc. Dividends
Year Dividends Growth

THC Therapeutics, Inc. Profile

About THC Therapeutics, Inc.

THC Therapeutics, Inc. operates in the wellness industry. It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. The company was formerly known as Millennium Blockchain, Inc. and changed its name to THC Therapeutics, Inc. in September 2018. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada.

CEO
Mr. Scott A. Cox
Employee
1
Address
11700 W Charleston Boulevard
Las Vegas, 89135

THC Therapeutics, Inc. Executives & BODs

THC Therapeutics, Inc. Executives & BODs
# Name Age
1 Mr. Scott A. Cox
Chief Executive Officer, Chief Financial Officer & Director
70
2 Mr. Brandon Romanek
Chief Information Officer, Treasurer, Founder, President, Secretary & Chairman
70
3 Mr. Victor Nacif
Head of Design
70

THC Therapeutics, Inc. Competitors